利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

111 条记录 (耗时 0.083 秒)

    Recombinant IL-9 antibodies and uses thereof
    73.
    发明授权
    Recombinant IL-9 antibodies and uses thereof 失效
    重组IL-9抗体及其用途

    公开(公告)号：US08481037B2

    公开(公告)日：2013-07-09

    申请号：US13007211

    申请日：2011-01-14

    申请人： Jennifer Lynne Reed ,  Herren Wu ,  Ying Tang ,  Julian Davies ,  Jeffry Watkins

    发明人： Jennifer Lynne Reed ,  Herren Wu ,  Ying Tang ,  Julian Davies ,  Jeffry Watkins

    IPC分类号： A61K39/395

    CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

    摘要： The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

    摘要翻译： 本发明提供免疫特异性结合IL-9多肽的新型抗体和包含所述抗体的组合物。 本发明还提供了预防，治疗，治疗和/或改善与IL 9或IL-9受体或其亚基的异常表达和/或活性相关的疾病和病症的方法和组合物，自身免疫性疾病，炎性疾病，增殖性疾病， 以及感染，其包括施用一种或多种免疫特异性结合IL-9多肽的抗体。 本发明还包括用于诊断，监测和预测这些疾病的方法和组合物。 本发明还涉及包含免疫特异性结合IL-9多肽的抗体的制品和试剂盒。

    Method of identifying membrane Ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
    74.
    发明授权
    Method of identifying membrane Ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells 有权
    鉴定膜Ig特异性抗体的方法及其用于靶向产生免疫球蛋白的前体细胞的用途

    公开(公告)号：US08404236B2

    公开(公告)日：2013-03-26

    申请号：US13372170

    申请日：2012-02-13

    申请人： Herren Wu ,  Peter Kiener ,  Partha S. Chowdhury ,  James F. Young

    发明人： Herren Wu ,  Peter Kiener ,  Partha S. Chowdhury ,  James F. Young

    IPC分类号： A61K39/00

    CPC分类号： G01N33/56972 ,  A61K2039/505 ,  C07K16/4291 ,  C07K2317/52 ,  C07K2317/55 ,  Y10S424/805 ,  Y10S530/862 ,  Y10S530/868

    摘要： The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells.

    摘要翻译： 本发明涉及结合存在于膜锚定的免疫球蛋白上并与B细胞和浆细胞表面上的这些新表位结合的抗体的发现。 此外，本发明的抗体可以介导ADCC，并且可用于消耗表达本发明的新表位的那些B细胞和浆细胞。 本发明的抗体可用于治疗由B细胞的单克隆扩增引起的B细胞介导的疾病和疾病。 因此，本发明还提供了用于预防，治疗或改善由B细胞的单克隆扩增引起的B细胞介导的疾病和疾病的组合物和方法。

    Integrated approach for generating multidomain protein therapeutics
    76.
    发明授权
    Integrated approach for generating multidomain protein therapeutics 失效
    用于产生多结构域蛋白治疗剂的综合方法

    公开(公告)号：US08309690B2

    公开(公告)日：2012-11-13

    申请号：US11993680

    申请日：2006-06-30

    申请人： Christian Allan ,  Herren Wu ,  Jeffrey Swers ,  William Dall'Acqua

    发明人： Christian Allan ,  Herren Wu ,  Jeffrey Swers ,  William Dall'Acqua

    IPC分类号： C07K16/00

    CPC分类号： C07K16/00 ,  A61K39/39591 ,  C07K2317/52 ,  C07K2317/55

    摘要： The invention provides method for therapeutic protein drug development that incorporates therapeutic and/or formulation and/or manufacturing considerations in the early screening process. The approach involves screening a plurality of different variants of a domain that have been determined to have the desired therapeutic property to identify one or more variants that have desired therapeutic and/or formulation characteristics, and constructing the full multidomain proteins using the identified domain variants. The present invention also provides a method for determining the shelf life of multidomain proteins in formulations. The method comprises determining a thermal denaturation and/or renaturation curve of a domain of the protein whose unfolding leads to aggregation of the protein in a solution. The method evaluates the shelf life of the multidomain protein based on the denaturation/renaturation curve. The invention also provides methods for engineering multidomain proteins to improve their therapeutic and/or formulation characteristics.

    摘要翻译： 本发明提供了在早期筛选过程中结合治疗和/或制剂和/或制造考虑的治疗性蛋白质药物开发方法。 所述方法包括筛选已被确定具有所需治疗性质的结构域的多个不同变体以鉴定具有期望的治疗和/或制剂特征的一种或多种变体，以及使用鉴定的结构域变体构建完整的多结构域蛋白。 本发明还提供了一种确定制剂中多结构域蛋白质的保质期的方法。 该方法包括确定蛋白质的结构域的热变性和/或复性曲线，其解折叠导致蛋白质在溶液中聚集。 该方法基于变性/复性曲线评估多结构域蛋白质的保质期。 本发明还提供用于工程化多结构域蛋白质以改善其治疗和/或制剂特征的方法。

    METHODS OF PREVENTING AND TREATING RSV INFECTIONS AND RELATED CONDITIONS
    79.
    发明申请
    METHODS OF PREVENTING AND TREATING RSV INFECTIONS AND RELATED CONDITIONS 审中-公开
    预防和治疗RSV感染的方法及相关条件

    公开(公告)号：US20110158985A1

    公开(公告)日：2011-06-30

    申请号：US12969514

    申请日：2010-12-15

    申请人： GENEVIEVE LOSONSKY ,  EDWARD M. CONNOR ,  JAMES F. YOUNG ,  HERREN WU ,  WILLIAM DALL'ACQUA

    发明人： GENEVIEVE LOSONSKY ,  EDWARD M. CONNOR ,  JAMES F. YOUNG ,  HERREN WU ,  WILLIAM DALL'ACQUA

    IPC分类号： A61K39/42 ,  A61P31/14

    CPC分类号： C07K16/1027 ,  A61K2039/505 ,  A61K2039/543 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/72 ,  C07K2317/92 ,  C07K2317/94

    摘要： The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (kon) of at least 2×105 M−1 s−1 and a dissociation rate (koff) of less than 5×10−4 s−1.

    摘要翻译： 本发明提供了用于预防，治疗和/或改善呼吸道合胞病毒（RSV）感染（例如急性RSV疾病或RSV上呼吸道感染（URI））和/或下呼吸道感染（LRI）的方法， ），中耳炎（优选来源于，由RSV感染引起或与RSV感染相关联，例如RSV URI和/或LRI），和/或与其相关的症状或呼吸病症（例如，哮喘，喘息和/或 反应性气道疾病（RAD）），包括向所述人施用有效量的一种或多种以高亲和力和/或高亲合力免疫特异性结合一种或多种RSV抗原的抗体。 在一些实施方案中，一种或多种抗体包含修饰的IgG恒定结构域或其FcRn结合片段，导致更长的体内血清半衰期。 在具体实施方案中，本发明的方法包括施用有效量的一种或多种经免疫特异性结合一种或多种具有至少2×105M-1s-1的缔合率（kon）的RSV抗原的修饰的抗体，以及 解离速率（koff）小于5×10-4 s-1。

    Methods of Treating RSV Infections And Related Conditions
    80.
    发明申请
    Methods of Treating RSV Infections And Related Conditions 审中-公开
    治疗RSV感染和相关条件的方法

    公开(公告)号：US20110008329A1

    公开(公告)日：2011-01-13

    申请号：US12600292

    申请日：2008-06-25

    申请人： Subramaniam Krishnan ,  JoAnn Suzich ,  Peter Kiener ,  Genevieve Losonsky ,  Herren Wu ,  William Dall'Acqua ,  Bettina Richter

    发明人： Subramaniam Krishnan ,  JoAnn Suzich ,  Peter Kiener ,  Genevieve Losonsky ,  Herren Wu ,  William Dall'Acqua ,  Bettina Richter

    IPC分类号： A61K39/395 ,  C07K16/10 ,  A61P31/14 ,  A61P37/04

    CPC分类号： C07K16/1027 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/77

    摘要： The present invention provides methods for managing, treating and/or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), and/or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and/or wheezing and/or COPD in said patient.

    摘要翻译： 本发明提供了用于管理，治疗和/或改善呼吸道合胞病毒（RSV）感染（例如急性RSV疾病或RSV上呼吸道感染（URI）和/或下呼吸道感染（LRI））的方法， 和/或与受试者相关的症状或长期呼吸道状况（例如，哮喘，喘鸣，反应性气道疾病（RAD）或慢性阻塞性肺疾病（COPD））），包括向所述人施用有效量的 一种或多种以高亲和性和/或高亲合力免疫特异性结合一种或多种RSV抗原的抗体，并且还包含经修饰的IgG恒定结构域或其FcRn结合片段，以不仅降低RSV感染，而且减少pro - 炎症性上皮细胞免疫应答，以减轻所述患者中哮喘和/或喘息和/或COPD的后期发展。